Please login to the form below

Not currently logged in
Email:
Password:

Double-dose of cancer drug fails to meet target

Novartis has failed to prove that higher measures of its cancer drug, Glivec are more effective than the current dosage
Novartis has failed to prove in clinical trials that higher measures of its cancer drug, Glivec are more effective than the current dosage.

Trials of 800mg doses of Glivec in patients with chronic myeloid leukaemia (CML), showed no statistically significant improvement to patients treated with the standard 400mg dose.

The higher dose did however have an effect when used as the primary treatment for newly diagnosed patients with clinical milestones achieved significantly faster than with the 400mg dose.

"[The trial] reaffirms Glivec as the standard of care for newly diagnosed CML patients," said Dr Jorge Cortes, professor of medicine and deputy chair of Leukemia at the University of Texas. "We see a strong trend for rapid response with the 800mg doseÖ further follow up will be needed to assess what this rapid early response will mean in terms of long-term benefit."

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics